PRECIOSA trial
Phase 3 international study evaluating the use of continuous albumin administration in reverting cirrhosis progression.5 We have demonstrated that albumin dysfunction correlates with disease markers of cirrhosis,6 and recent clinical data have already shown an increase in albumin levels along with a reduction in systemic inflammation in patients with decompensated cirrhosis following albumin treatment.7